Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM
#MEDIA: Announcing the final analysis of OS from the CheckMate -816 trial evaluating our #immunotherapy used in combination with chemotherapy regimen as neoadjuvant treatment of resectable non-small cell #lungcancer. #NSCLC#LCSMbit.ly/4k3VFJq
Well done @michaelconroy on a superb poster presentation at #SITC24 on our work exploring how longitudinal changes in the gut microbiome impact outcomes from neoadjuvant IO in several prospective NSCLC trials @HopkinsThoracic
Thanks @lcfamerica@IASLC for funding this work #LCSM
This is HOPE. Patient #2 in the Peptide vaccine ALK NSCLC clinical trial! We are hopeful this groundbreaking vaccine will turn this terminal disease into a chronic one. I believe in my doctor as much as he believes in me. @ALKPositiveinc@oncodaily@OncogeneCancer@OncoAlert
Dr. @jennifermarksmd breaks down latest data for Trastuzumab Deruxtecan in HER2-overexpressing solid tumors including NSCLC at #LungCancerSymposium. Rapidly evolving space & need more prospective data to ID pts most likely to respond such as concurrent HER2 amp. @LombardiCancer
So fortunate to celebrate the holiday season with the @MolecularOncLab! Cannot think of a more dynamic, creative and more importantly good-hearted group of people🙏
Fascinating tour through molecular profiling of pancreatic cancer from a brilliant 🇮🇪 researcher @graokane . Collaboration is key to thrive and for us non-pancreatic people: it’s a lot more than KRAS 😮